Electro-bioassay for early detection of neurodegenerative diseases

Overview

CytoEM Innovations introduces an advanced electro-bioassay designed to detect neurodegenerative diseases at an early stage by targeting the electrical properties of cytoskeletal elements such as microtubules. This innovative assay identifies unique bioelectric signatures that can serve as biomarkers, offering a promising diagnostic tool for conditions like Alzheimer's, Parkinson's, and ALS. By analyzing these electrical signatures, the bioassay provides a method to differentiate between various neurodegenerative diseases and aids in the development of targeted treatments.

Technical specifications

• Cytoskeletal Isolation: Microtubules and their components are isolated from neurons relevant to specific diseases.
• Disease Simulation: Pathological states are simulated by introducing proteins that mimic disease conditions.
• Electrical Recording: The oscillatory behaviors of microtubules are measured under both healthy and pathological conditions.
• Bioelectric Profiling: Establishes electrical profiles for normal and diseased states, linking changes to known phenotypes.
• Drug Screening Capabilities: Tests the effects of potential treatments on cytoskeletal bioelectric properties, expanding to include astrocytes and microglia to model neuroinflammation.

Technology readiness level

Currently at TRL 3, this technology is in the active research and development phase with experimental proof of concept established. The next steps include further validation and optimization, followed by application in drug screening and therapeutic development.